CLDX
Celldex Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
30.80
▼ 1.79 (5.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
31.78
Prev close
32.59
Day high
32.68
Day low
30.85
Volume
1.77M
Market cap
$2.43B
P/E (TTM)
—
52W range
22.10 – 45.14
Day trading desk
Gap from prior close
-2.49%
Prior close 32.59
VWAP
31.12
-1.01% from price
Relative volume
2.62×
Unusually busy
Session range
18.33%
30.00 – 35.50
Position in range
15%
Near session low
ATR (14D)
2.17
7.03% of price
Prior day high
32.88
PDH
Prior day low
31.50
PDL
Bid / ask spread
—
Quote not published
Session volume
3.33M
Avg 1.27M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.99%
-3.9%
1M
-21.85%
-23.0%
3M
-20.41%
-24.9%
6M
-1.08%
-19.3%
YTD
+14.18%
-0.1%
1Y
+17.42%
+1.0%
3Y
+12.68%
-69.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CLDX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
212.81K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jan 2, 26 | MARTIN SAMUEL BATES Chief Financial Officer |
CONVERSION | 4.82K | $50.00K | Direct |
| Dec 15, 25 | PEPIN RONALD A Officer |
CONVERSION | 19.33K | $105.71K | Direct |
| Dec 4, 25 | JIMENEZ FREDDY A General Counsel |
SELL | 4.17K | $121.21K | Direct |
| Nov 13, 25 | WRIGHT RICHARD M Former |
CONVERSION | 49.30K | $692.91K | Direct |
| Nov 13, 25 | WRIGHT RICHARD M Former |
SELL | 49.30K | $1.18M | Direct |
| Aug 13, 25 | JIMENEZ FREDDY A General Counsel |
SELL | 771 | $19.10K | Direct |
| Nov 18, 24 | MARINO JAMES J Director |
STOCK | 10.50K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
JIMENEZ FREDDY A |
General Counsel | 30.80K | Sale |
MARINO JAMES J |
Director | 2.20K | Stock Gift |
MARTIN SAMUEL BATES |
Chief Financial Officer | 32.94K | Conversion of Exercise of derivative security |
PEPIN RONALD A |
Officer | 20.10K | Conversion of Exercise of derivative security |
WRIGHT RICHARD M |
Former | 20.83K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$2.43B
Enterprise value$1.72B
Revenue (TTM)$158.00K
Gross profit$-278.65M
EBITDA$-322.43M
Net income$-300.55M
EPS (TTM)$-4.35
Free cash flow$-133.08M
Total cash$717.59M
Total debt$4.90M
Book value / share$9.10
Shares outstanding78.53M
Float73.02M
Short % of float13.53%
Dividend yield0.00%
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.32
PEG ratio—
Price / sales—
Price / book3.41
EV / revenue10,899.53
EV / EBITDA-5.34
Gross margin0.00%
Operating margin-366468.20%
Profit margin0.00%
Return on equity-43.88%
Return on assets-27.62%
Debt / equity0.69
Current ratio11.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.54M | $7.02M | $6.88M | $2.36M | — | -78.0% |
| Operating revenue | $1.54M | $7.02M | $6.88M | $2.36M | — | -78.0% |
| Research & development | $245.07M | $163.55M | $118.01M | $82.26M | — | +49.8% |
| Selling, general & admin | $43.84M | $38.55M | $30.91M | $27.20M | — | +13.7% |
| Total operating expense | $288.91M | $202.10M | $148.93M | $109.45M | — | +43.0% |
| Operating income | -$287.37M | -$195.08M | -$142.04M | -$107.10M | — | -47.3% |
| Pre-tax income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | — | -63.9% |
| Tax provision | — | — | $0 | $0 | -$227.00K | — |
| Net income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | — | -63.9% |
| Net income to common | -$258.76M | -$157.86M | -$141.43M | -$112.33M | — | -63.9% |
| Basic EPS | -3.90 | -2.45 | -2.92 | -2.40 | — | -59.2% |
| Diluted EPS | -3.90 | -2.45 | -2.92 | -2.40 | — | -59.2% |
| EBIT | -$287.37M | -$195.08M | -$142.04M | -$107.10M | — | -47.3% |
| EBITDA | -$283.99M | -$191.90M | -$139.03M | -$104.20M | — | -48.0% |
| Basic shares | 66.42M | 64.39M | 48.45M | 46.89M | — | +3.1% |
| Diluted shares | 66.42M | 64.39M | 48.45M | 46.89M | — | +3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $28.87M | $28.36M | $34.81M | $29.43M | +1.8% |
| Cash & short-term investments | $518.57M | $725.28M | $423.60M | $304.95M | -28.5% |
| Accounts receivable | $2.02M | $700.00K | $2.63M | $347.00K | +187.9% |
| Total current assets | $534.66M | $747.16M | $431.69M | $317.69M | -28.4% |
| Property, plant & equipment | $7.77M | $8.24M | $6.64M | $7.75M | -5.7% |
| Goodwill & intangibles | $27.19M | $27.19M | $27.19M | $27.19M | 0.0% |
| Total assets | $582.98M | $792.34M | $465.63M | $352.74M | -26.4% |
| Total current liabilities | $50.99M | $39.50M | $31.13M | $18.61M | +29.1% |
| Total debt | $2.34M | $3.81M | $2.54M | $4.03M | -38.7% |
| Total liabilities | $55.82M | $45.34M | $36.46M | $26.53M | +23.1% |
| Retained earnings | -$1.81B | -$1.56B | -$1.40B | -$1.26B | -16.6% |
| Shareholder equity | $527.16M | $747.00M | $429.17M | $326.20M | -29.4% |
| Working capital | $483.67M | $707.66M | $400.57M | $299.08M | -31.7% |
| Net tangible assets | $499.98M | $719.82M | $401.98M | $299.01M | -30.5% |
| Shares issued | 66.55M | 66.37M | 55.88M | 47.20M | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | -63.9% |
| Depreciation & amortisation | $3.38M | $3.18M | $3.01M | $2.90M | +6.4% |
| Stock-based compensation | $36.22M | $34.24M | $23.89M | $15.61M | +5.8% |
| Change in working capital | $14.06M | -$21.60M | $13.46M | -$3.90M | +165.1% |
| Operating cash flow | -$210.94M | -$157.78M | -$107.29M | -$103.73M | -33.7% |
| Capital expenditure | -$2.71M | -$1.92M | -$1.82M | -$1.83M | -41.4% |
| Investing cash flow | $209.07M | -$290.13M | -$105.78M | $89.94M | +172.1% |
| Financing cash flow | $2.39M | $441.45M | $218.46M | $4.08M | -99.5% |
| Free cash flow | -$213.66M | -$159.70M | -$109.11M | -$105.56M | -33.8% |
| End cash position | $28.87M | $28.36M | $34.81M | $29.43M | +1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $22.00K | $15.00K | $121.00K | $0 | $730.00K | +46.7% |
| Operating revenue | $22.00K | $15.00K | $121.00K | $0 | $730.00K | +46.7% |
| Research & development | $67.54M | $73.00M | $75.33M | $62.93M | $54.20M | -7.5% |
| Selling, general & admin | $13.10M | $11.45M | $11.94M | $10.69M | $10.39M | +14.4% |
| Total operating expense | $80.64M | $84.45M | $87.27M | $73.62M | $64.59M | -4.5% |
| Operating income | -$80.62M | -$84.44M | -$87.15M | -$73.62M | -$63.86M | +4.5% |
| Pre-tax income | -$73.50M | -$78.69M | -$81.32M | -$67.04M | -$56.60M | +6.6% |
| Net income | -$73.50M | -$78.69M | -$81.32M | -$67.04M | -$56.60M | +6.6% |
| Net income to common | -$73.50M | -$78.69M | -$81.32M | -$67.04M | -$56.60M | +6.6% |
| Basic EPS | -0.94 | -1.18 | -1.22 | -1.01 | -0.85 | +20.3% |
| Diluted EPS | -0.94 | -1.18 | -1.22 | -1.01 | -0.85 | +20.3% |
| EBIT | -$80.62M | -$84.44M | -$87.15M | -$73.62M | -$63.86M | +4.5% |
| EBITDA | -$79.72M | -$83.58M | -$86.34M | -$72.79M | -$62.98M | +4.6% |
| Basic shares | 77.84M | 66.57M | 66.49M | 66.42M | 66.39M | +16.9% |
| Diluted shares | 77.84M | 66.57M | 66.49M | 66.42M | 66.39M | +16.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $47.45M | $35.73M | $28.87M | $36.04M | $23.04M | +32.8% |
| Cash & short-term investments | $717.59M | $451.46M | $518.57M | $583.22M | $630.34M | +58.9% |
| Accounts receivable | $230.00K | $230.00K | $2.02M | $90.00K | $90.00K | 0.0% |
| Total current assets | $724.93M | $459.22M | $534.66M | $604.34M | $648.40M | +57.9% |
| Property, plant & equipment | $14.79M | $9.41M | $7.77M | $7.55M | $7.51M | +57.2% |
| Goodwill & intangibles | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M | 0.0% |
| Total assets | $782.35M | $511.25M | $582.98M | $648.44M | $692.41M | +53.0% |
| Total current liabilities | $61.33M | $51.47M | $50.99M | $46.47M | $32.96M | +19.1% |
| Total debt | $4.90M | $1.91M | $2.34M | $2.62M | $3.03M | +157.0% |
| Total liabilities | $67.78M | $55.03M | $55.82M | $50.08M | $37.00M | +23.2% |
| Retained earnings | -$1.97B | -$1.89B | -$1.81B | -$1.73B | -$1.67B | -3.9% |
| Shareholder equity | $714.56M | $456.23M | $527.16M | $598.36M | $655.41M | +56.6% |
| Working capital | $663.61M | $407.75M | $483.67M | $557.87M | $615.44M | +62.7% |
| Net tangible assets | $687.37M | $429.04M | $499.98M | $571.17M | $628.22M | +60.2% |
| Shares issued | 78.50M | 66.57M | 66.55M | 66.45M | 66.39M | +17.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$73.50M | -$78.69M | -$81.32M | -$67.04M | -$56.60M | +6.6% |
| Depreciation & amortisation | $902.00K | $854.00K | $816.00K | $824.00K | $873.00K | +5.6% |
| Stock-based compensation | $8.41M | $8.52M | $8.91M | $8.80M | $9.19M | -1.3% |
| Change in working capital | $8.48M | $4.35M | $8.53M | $9.80M | $4.22M | +95.1% |
| Operating cash flow | -$57.41M | -$65.59M | -$63.94M | -$48.63M | -$44.01M | +12.5% |
| Capital expenditure | -$3.18M | -$1.64M | -$1.28M | -$440.00K | -$728.00K | -94.0% |
| Investing cash flow | -$255.52M | $72.12M | $55.42M | $60.85M | $49.85M | -454.3% |
| Financing cash flow | $324.66M | $327.00K | $1.35M | $774.00K | $63.00K | +99,183.5% |
| Free cash flow | -$60.59M | -$67.23M | -$65.22M | -$49.07M | -$44.73M | +9.9% |
| End cash position | $47.45M | $35.73M | $28.87M | $36.04M | $23.04M | +32.8% |
Options analytics
Put / call volume
3.01
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
15.00
-51.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
199
Contracts, this expiry
Put volume
599
Contracts, this expiry
Heaviest call OI
46.00
3 contracts
Heaviest put OI
15.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.06 | -0.94 | +11.4% |
| Mar 2026 | -1.13 | -1.18 | -4.2% |
| Dec 2025 | -1.00 | -1.22 | -22.5% |
| Sep 2025 | -0.89 | -1.01 | -13.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.01 | 10 | $883.22K | 0.0% |
| Next quarter | -1.01 | 10 | $1.36M | +1,023.0% |
| Current year | -4.12 | 10 | $1.85M | +19.7% |
| Next year | -4.24 | 10 | $9.95M | +438.1% |
Analyst targets & ownership
Mean target$63.07
High target$100.00
Low target$28.00
Implied upside104.78%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy2 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders0.27%
Held by institutions110.27%
Institutions holding342
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
31.67
-2.74% from price
SMA 20
34.77
-10.82% from price
SMA 50
38.14
-18.70% from price
SMA 100
35.87
-14.14% from price
SMA 200
32.39
-4.26% from price
EMA 12
32.90
-6.38% from price
EMA 26
34.93
-11.83% from price
EMA 50
36.15
-14.79% from price
RSI (14)
31.6
Neutral
MACD (12,26,9)
-2.04
Hist -0.20
ATR (14)
2.17
6.99% of price
Realised vol 30D
50.9%
Annualised
Bollinger upper
41.42
20, 2σ
Bollinger lower
28.13
20, 2σ
50 / 200 cross
Golden
38.14 vs 32.39
Trend bias
Below 200
-4.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.21
More volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
50.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.9%
Peak to trough
Max drawdown 5Y
-72.5%
Peak to trough
ATR 14
2.17
6.99% of price
Beta (reported)
0.90
5Y monthly, from filing
Short interest
Shares short
8.95M
Prior 7.57M
Change vs prior
+18.3%
Shorts adding
% of float
13.53%
Elevated
% of shares out
11.40%
Against total outstanding
Days to cover
12.6
Crowded exit
Float
73.02M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 23, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 23, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 22, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 10, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 29, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 22, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 22, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 22, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateFeb 11, 2019
Last split1:15
Split dateFeb 11, 2019
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-22
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-15
Offering Registrations
S-8 · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-02
Periodic Financial Reports
10-K · 2026-02-25
Headlines
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
Insider Monkey · 14d ago
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Zacks · 14d ago
Top Midday Decliners
MT Newswires · 14d ago
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
Stocktwits · 15d ago
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
MarketBeat · 15d ago
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
Zacks · 15d ago
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
InvestorsHub · 15d ago
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
MT Newswires · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.